NCT00781612 2025-12-24A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent StudiesGenentech, Inc.Phase 2 Active not recruiting720 enrolled
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT01835236 2021-03-30Trastuzumab & Pertuzumab Followed by T-DM1 in MBCSwiss Cancer InstitutePhase 2 Completed208 enrolled